Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 May:106:108228.
doi: 10.1016/j.ijscr.2023.108228. Epub 2023 Apr 18.

Embryonal rhabdomyosarcoma of the prostate in a young male: A rare case report

Saad Alenezi  1 , Mohammed Zahir  2 , Jarah Alenezi  2
Affiliations
Case Reports

Embryonal rhabdomyosarcoma of the prostate in a young male: A rare case report

Saad Alenezi et al. Int J Surg Case Rep. 2023 May.

Abstract

Introduction and importance: Embryonal rhabdomyosarcoma (ERMS) of the prostate is a rare disease, and it has a poor prognosis. Mostly patient come with late stage thus with delayed diagnosis and worse outcomes.

Case presentation: a 35-year-old Bangladeshi male presented with bladder outlet obstruction in an intermittent pattern. Patient was not complaining from any other urological symptoms, there was no hematuria or dysuria, even no constitutional symptoms, no history of weight loss, no anorexia or night rigors, also there was no history of fever. Patients have an only previous history of spinal screw without any other medical illnesses. Patient came to casualty with frequent visits without any inflammatory markers elevation even with normal biochemical labs. O/E he found to have a prostatic mass on PR examination of which patient admitted to urology department and underwent diagnostic cystoscopy which showed cauliflower mass at the prostatic urethra. Biopsies retrieved and showed embryonal rhabdomyosarcoma (RMS) of the prostate under the histopathological examination.

Clinical discussion: Embryonal rhabdomyosarcoma (ERMS) mostly care a poor prognosis and modalities vary according to the presentation and the stage. However distant metastasis is common at the time of presentation.

Conclusion: embryonal rhabdomyosarcoma of the prostate is a rare and aggressive tumor with a low survival rate in adults. However, more clinical data needed for a better outcome.

Keywords: Bladder outlet obstruction; Case report; Embryonal rhabdomyosarcoma; Prostate; Rhabdomyosarcoma.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement There are no conflicts of interest including any financial or personal relationships with other people or organisations or any work influencers.

Figures

Fig. 1
Fig. 1
a:Cystoscopy showing mixture of cauliflower and nodular growth. b:Cystoscopy showing Mixture of cauliflower and nodular growth.
Fig. 2
Fig. 2
a: EMRS is a very celluar tumor especially around blood vesseles (arrow). b: EMRS is a very celluar tumor especially around blood vesseles (arrow). c: a few scattered cells with moderate amount of eosinophilic cytoplasm (Rhabdomyoblasts) (arow). d: Desmin immunonmarker is positive in tumor cells. e: Histopathology report showing embryonal type of Rhabdomyosarcoma.
Fig. 3
Fig. 3
X-Ray chest showing pulmonary metastasis.
Fig. 4
Fig. 4
PSMA PET CT shoing focal expression adjacent to the left perphiral middle zone of enlarged prostste (SUVmax 7.1).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Skapek S.X., Ferrari A., Gupta A.A., Lupo P.J., Butler E., Shipley J., Barr F.G., Hawkins D.S. Rhabdomyosarcoma. Nat Rev Dis Primers. 2019;5(1):1. doi: 10.1038/s41572-018-0051-2. PMID: 30617281; PMCID: PMC7456566. - DOI - PMC - PubMed
    1. Clay MR. Embryonal rhabdomyosarcoma. PathologyOutlines.com website. https://www.pathologyoutlines.com/topic/softtissueembryonalrhabdo.html. Accessed March 17th, 2023.
    1. Russo P., Brady M.S., Conlon K. Adult urological sarcoma. J. Urol. 1992;147(4):1032–1036. doi: 10.1016/s0022-5347(17)37456-6. [PubMed] [CrossRef] [Google Scholar] - DOI - PubMed
    1. Kojima Y., Hashimoto K., Ando M. Clinical outcomes of adult and childhood rhabdomyosarcoma treated with vincristine, D-actinomycin, and cyclophosphamide chemotherapy. J. Cancer Res. Clin. Oncol. 2012;138(7):1249–1257. doi: 10.1007/s00432-012-1199-x. [PubMed] [CrossRef] [Google Scholar] - DOI - PMC - PubMed
    1. Arndt C.A., Stoner J.A., Hawkins D.S., Rodeberg D.A., Hayes-Jordan A.A., Paidas C.N., Parham D.M., Teot L.A., Wharam M.D., Breneman J.C., Donaldson S.S., Anderson J.R., Meyer W.H. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. J. Clin. Oncol. 2009;27(31):5182–5188. doi: 10.1200/JCO.2009.22.3768. Epub 2009 Sep 21. PMID: 19770373; PMCID: PMC2773476. - DOI - PMC - PubMed

Publication types